Archives of Clinical Infectious Diseases

Published by: Kowsar

Tuberculosis: Treatment-related Problems and Future Facets

Mohammad Asif 1 , *
Author Information
1 Department of Pharmacy, GRD (PG) Institute of Management and Technology, Dehradun, India
Article information
  • Archives of Clinical Infectious Diseases: April 24, 2013, 8 (2); e14413
  • Published Online: April 17, 2013
  • Article Type: Review Article
  • Received: October 16, 2012
  • Revised: November 15, 2012
  • Accepted: January 10, 2013
  • DOI: 10.5812/archcid.14413

To Cite: Asif M. Tuberculosis: Treatment-related Problems and Future Facets, Arch Clin Infect Dis. 2013 ; 8(2):e14413. doi: 10.5812/archcid.14413.

Abstract
Copyright © 2013, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Chronic diseases and their common risk factors. 2005;
  • 2. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA. 1999; 282(7): 677-86[PubMed]
  • 3. Moran N. WHO issues another gloomy tuberculosis report. Nat Med. 1996; 2(4): 377[PubMed]
  • 4. Okada M, Kobayashi K. [Recent progress in mycobacteriology]. Kekkaku. 2007; 82(10): 783-99[PubMed]
  • 5. Tomioka H, Namba K. [Development of antituberculous drugs: current status and future prospects]. Kekkaku. 2006; 81(12): 753-74[PubMed]
  • 6. Espinal MA. The global situation of MDR-TB. Tuberculosis (Edinb). 2003; 83(1-3): 44-51[PubMed]
  • 7. Asif M. Study of clinically used and recently developed antimycobacterial agents. Oriental Pharm Exp Med. 2012; 12(1): 15-34[DOI]
  • 8. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol. 2007; 3(9): 541-8[DOI][PubMed]
  • 9. Donald PR, van Helden PD. The global burden of tuberculosis--combating drug resistance in difficult times. N Engl J Med. 2009; 360(23): 2393-5[DOI][PubMed]
  • 10. Dony JF, Ahmad J, Khen Tiong Y. Epidemiology of tuberculosis and leprosy, Sabah, Malaysia. Tuberculosis (Edinb). 2004; 84(1-2): 8-18[PubMed]
  • 11. Asif M, Siddiqui AA, Husain A. Quinolone derivatives as antitubercular drugs. Med Chem Res. 2013; 22(3): 1029-42[DOI]
  • 12. Kamal A, Azeeza S, Malik MS, Shaik AA, Rao MV. Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds. J Pharm Pharm Sci. 2008; 11(2): 56s-80s[PubMed]
  • 13. Asif M. Study of currently used antimycobacterials, their analogoues and recently developed agents. Indian drugs. 2012; 49(7): 5-19
  • 14. Asif M. A review of antimycobacterial drugs in development. Mini Rev Med Chem. 2012; 12(13): 1404-18[PubMed]
  • 15. Farmer P, Bayona J, Becerra M, Furin J, Henry C, Hiatt H, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998; 2(11): 869-76[PubMed]
  • 16. WHO Report 2008 global tuberculosis control - surveillance, planning, financing. 2008;
  • 17. Telenti A, Iseman M. Drug-resistant tuberculosis: what do we do now? Drugs. 2000; 59(2): 171-9
  • 18. Tripathi RP, Tewari N, Dwivedi N, Tiwari VK. Fighting tuberculosis: an old disease with new challenges. Med Res Rev. 2005; 25(1): 93-131[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments